Meeting
2016 ASCO Annual Meeting
Validation of a thrombosis risk assessment model in patients with newly diagnosed multiple myeloma.
Authors
Brea Lipe
University of Kansas Medical Center, Kansas City, KS
Brea Lipe , Hailey Baker , Brandon Weckbaugh , Carol Webb , Alexandra Brown , Jonathan Mahnken , Theresa Shireman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8055)
DOI
10.1200/JCO.2016.34.15_suppl.8055
Abstract #
8055
Poster Bd #
320
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).
First Author: Brigitte Pegourie
Poster
2016 ASCO Quality Care Symposium
Utilization and effectiveness of extended-duration thromboprophylaxis after high-risk abdominopelvic cancer surgery.
First Author: Jason Dennis Wright
Poster
2014 ASCO Annual Meeting
Variation in hospital thromboprophylaxis rates for abdominal cancer surgery.
First Author: Robert Wallace Krell
Poster
2023 ASCO Quality Care Symposium
Impact of integrating standardized venous thromboembolism (VTE) prophylaxis orders for patients with multiple myeloma into an electronic health record (EHR).
First Author: Andrea Dickens